Valuation: Insmed Incorporated

Market Cap 27.47B 23.53B 22.01B 20.15B 37.82B 2,628B 38.32B 260B 101B 1,320B 103B 101B 4,366B P/E 2026 *
-79.5x
P/E 2027 * 124x
Enterprise Value 26.83B 22.99B 21.51B 19.69B 36.95B 2,567B 37.44B 254B 99.09B 1,290B 101B 98.57B 4,266B EV / Sales 2026 *
14.9x
EV / Sales 2027 * 9.18x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+0.55%
1 week+1.64%
Current month+27.56%
1 month+17.94%
3 months+18.38%
6 months-23.73%
Current year-27.74%
1 week 124.6
Extreme 124.6
131.1
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Fiscal year

Chief Operating Officer

719,550 0.3320%
8/6/26 Fiscal year

Chief Technology Officer

81,519 0.0376%
Change 5-day change 1-year change 3-year change Capi.($)
+0.55%+1.64%-4.63%+480.92% 27.47B
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
-0.41%+0.54%+308.39%+206.94% 12.3B
Average +1.09%+7.59%+84.02%+198.60% 30.18B
Weighted average by Cap. +0.69%+9.12%+68.23%+159.86%

Financials

2026 *2027 *
Net sales 1.81B 1.55B 1.45B 1.33B 2.49B 173B 2.52B 17.11B 6.67B 86.82B 6.78B 6.64B 287B 2.87B 2.46B 2.3B 2.1B 3.95B 274B 4B 27.15B 10.59B 138B 10.77B 10.53B 456B
Net income -349M -299M -280M -256M -481M -33.43B -487M -3.31B -1.29B -16.79B -1.31B -1.28B -55.54B 194M 166M 156M 142M 267M 18.58B 271M 1.84B 717M 9.33B 729M 713M 30.87B
Net Debt -632M -541M -506M -464M -870M -60.45B -881M -5.98B -2.33B -30.37B -2.37B -2.32B -100B -1.16B -991M -927M -849M -1.59B -111B -1.61B -10.95B -4.27B -55.59B -4.34B -4.25B -184B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-21 US$125.77 +0.55% 1,124,491
26-08-20 US$125.08 -4.27% 1,761,850
26-08-19 US$130.66 +1.71% 1,493,674
26-08-18 US$128.46 +0.11% 1,274,119
26-08-17 US$128.32 +3.70% 1,899,670
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
125.77USD
Average target price
200.05USD
Spread / Average Target
+59.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock